迈普医学 (301033.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	373.5M	368.8M	278.4M	230.9M	195.3M
Cost of Revenue	75.2M	72.9M	57.6M	41.5M	31.2M
Gross Profit	298.3M	295.9M	220.9M	189.3M	164.0M
Operating Expenses
R&D Expense	37.9M	37.0M	27.1M	26.8M	30.6M
SG&A Expense	—	—	—	—	—
General & Admin Expense	74.7M	73.0M	56.8M	54.4M	35.3M
Selling & Marketing Expense	68.7M	66.5M	57.2M	61.7M	70.3M
Other Expenses	—	—	—	—	—
Total Operating Expenses	188.8M	182.3M	145.0M	148.1M	138.1M
Cost and Expenses	264.0M	255.2M	202.6M	189.6M	169.4M
Operating Income (EBIT)	123.2M	128.0M	91.7M	48.3M	41.3M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	121.6M	126.2M	93.2M	48.0M	40.0M
Income Tax Expense	11.9M	13.0M	14.3M	7.1M	4.2M
Bottom Line
Net Income	109.7M	113.1M	78.9M	40.9M	35.9M
Earnings from Cont. Ops	109.7M	113.1M	78.9M	40.9M	35.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	109.7M	113.1M	78.9M	40.9M	35.9M
Per Share
Basic EPS	CN¥1.65	CN¥1.71	CN¥1.20	CN¥0.62	CN¥0.54
Diluted EPS	CN¥1.65	CN¥1.69	CN¥1.20	CN¥0.62	CN¥0.54
Revenue Per Share	CN¥5.59	CN¥5.58	CN¥4.24	CN¥3.50	CN¥2.94
Shares
Basic Shares Outstanding	66.8M	66.2M	65.7M	65.9M	66.5M
Diluted Shares Outstanding	66.8M	66.2M	65.7M	65.9M	66.5M
Profitability Metrics
EBITDA	—	155.3M	118.2M	73.4M	55.9M
D&A	—	27.3M	26.5M	25.1M	14.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026